M&A / Deals Parexel buys Vitrana to boost patient safety toolkit PharmaphorumContract research organisation Parexel has bought Vitrana and its AI-powered pharmacovigilance platform for an undisclosed sum.Read full story pharminent April 30, 2026 (Last updated: May 1, 2026) Pharmaphorum Contract research organisation Parexel has bought Vitrana and its AI-powered pharmacovigilance platform for an undisclosed sum. Read full story Post navigation Previous: UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapyNext: Merck still sees ‘compelling’ outlook for Terns leukemia drug Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
